drugset / Trial / NCT07386626

Tegileridine Combined With Intercostal Nerve Block After Thoracoscopic Lung Resection

NCT07386626

Recruiting 118 enrolled Tongji Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

Combining tegileridine PCIA with ICNB targeting peripheral nerves, may constitute an ideal analgesic model with complementary advantages. Thus potentially achieving the analgesic goal of "early pain relief, stable throughout the process, and rapid recovery," and may have a positive impact on reducing CPSP.

Timeline

Start
2026-03-18
Primary completion
2026-12-31
Completion
2027-01-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sufentanil Other / unclassified 0.15 ug/kg Intravenous
Subject Tegileridine Small molecule 0.015 mg/kg Intravenous

Indications

No indication recorded.